Medigen Vaccine Biologics Corporation (TPEX:6547)

Medigen Vaccine Biologics Revenue

Medigen Vaccine Biologics had revenue of 105.93M TWD in the quarter ending March 31, 2026, a decrease of -8.23%. This brings the company's revenue in the last twelve months to 603.68M, down -8.87% year-over-year. In the year 2025, Medigen Vaccine Biologics had annual revenue of 613.17M with 1.24% growth.

• Revenue (ttm): 603.68M
• Revenue Growth: -8.87%
• P/S Ratio: 24.61
• Revenue / Employee: 5.86M
• Employees: 103
• Market Cap: 14.86B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	613.17M	7.53M	1.24%
Dec 31, 2024	605.64M	216.01M	55.44%
Dec 31, 2023	389.62M	24.58M	6.73%
Dec 31, 2022	365.04M	-2.92B	-88.87%
Dec 31, 2021	3.28B	3.27B	28,413.03%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 28, 2026

Data Sources Report a data error